TEM
The headline: still growing like a startup on espresso
Tempus AI said it reported first-quarter 2026 results on May 5th, and the numbers came in hot enough to make a growth investor smile. Revenue hit $348.1 million, up 36.1% from a year ago, which is the kind of print that keeps the “AI in healthcare” story alive and kicking.
Diagnostics is doing the heavy lifting
The real engine here was diagnostics, which brought in $261.1 million and grew 34.7% year over year. Oncology volume jumped 28%, and MRD testing looked downright caffeinated at about 6,500 tests in the quarter, up roughly 500% from last year.
That matters because Tempus isn’t just selling a neat-sounding AI pitch deck. It’s trying to turn precision medicine into an actual business, and the diagnostics business is where the rubber meets the road. More tests usually means more data, more workflow integration, and more reasons for hospitals and clinicians to keep using the platform.
The investor question: can growth stay this strong?
Tempus also reported $87.0 million in data and applications revenue, which adds another piece to the puzzle. For investors, the big thing is whether this growth is durable and profitable, or whether the company is still in the expensive “build now, brag later” phase.
Big picture: Tempus is still behaving like a company that wants to be a core AI layer in medicine, not just another ticker with “AI” in the pitch. The growth story looks healthy — now the market will want to see how efficiently it can keep feeding that machine.